Merck raises revenue forecast while cutting profit outlook after Terns acquisition charge

Merck & Co., Inc. has lowered its earnings guidance for the current fiscal year after announcing a charge related to its recent acquisition of Terns Pharmaceuticals. The company said the unexpected cost, which is tied to the integration of the biotech firm, has reduced its projected profitability.

The charge stems from the acquisition of Terns, a specialty biopharma that focuses on developing therapies for rare diseases. Merck disclosed that the expense, which was not fully accounted for in the original acquisition plan, will impact its operating margin for the year. While the company remains committed to the strategic fit of Terns in its pipeline, the revised guidance reflects a more conservative outlook as it absorbs the additional costs.

Looking ahead, Merck indicated that it will continue to monitor the integration process and adjust its financial forecasts as further details emerge. The company maintains that its long‑term growth strategy remains intact, though it will now operate with a tighter margin until the integration benefits materialize.